The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study

Table 3 Comparisons of risk for acute coronary syndrome between study cohorts ^a

Cohort/risk window	Biologic-naïve RA comparator		General population comparator
	HR ^b(95% CI)	HR ^c(95% CI)	HR ^b(95% CI)	HR ^c(95% CI)
TNFi-treated RA
Ever-exposed	0.81 (0.69 to 0.94)	0.82 (0.70 to 0.95)	1.93 (1.66 to 2.25)	1.61 (1.36 to 1.92)
Actively on TNFi	0.71 (0.58 to 0.86)	0.73 (0.60 to 0.89)	1.73 (1.43 to 2.10)	1.50 (1.21 to 1.85)
Short-term exposure	0.75 (0.58 to 0.97)	0.78 (0.61 to 1.01)	2.07 (1.59 to 2.70)	1.65 (1.23 to 2.22)
Biologic-naïve RA comparator
Ever-exposed	–	–	2.35 (2.11 to 2.63)	2.03 (1.80 to 2.29)
Actively on TNFi	–	–	2.41 (2.11 to 2.76)	2.10 (1.82 to 2.43)
Short-term exposure	–	–	2.63 (2.21 to 3.13)	2.27 (1.89 to 2.73)

^aHR, Hazard ratio; RA, Rheumatoid arthritis; TNFi, Tumour necrosis factor inhibitor. ^bModel adjusted for age, sex and county of residence. ^cModel stratified for disability pension during the year before inclusion and adjusted for sex; age at time of inclusion; county of residence; year of inclusion; previous joint surgery; previous diagnosis of diabetes, hypertension, chronic obstructive pulmonary disease, cerebrovascular disease or other atherosclerotic disease; previous hospitalization for infectious disease; RA disease duration longer than 10 years (biologic-naïve and TNFi comparison); total number of days in hospital during 10 years prior to inclusion; sick leave; and education level.

ISSN: 1478-6362